181633-37-4

Basic information

• Product Name: 4-chloro-3-(3-pyridinyl)Benzenamine
• Synonyms: 4-chloro-3-(3-pyridinyl)Benzenamine
• CAS NO: 181633-37-4
• Molecular Weight: 204.659
• Mol File: 181633-37-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 4-chloro-3-(3-pyridinyl)Benzenamine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-3-(3-pyridinyl)Benzenamine(181633-37-4)
• EPA Substance Registry System: 4-chloro-3-(3-pyridinyl)Benzenamine(181633-37-4)

Safety Data

• Hazardous Substances Data: 181633-37-4(Hazardous Substances Data)

Upstream product

• 1692-25-7 3-pyridylboronic acid 
• 626-55-1 3-Bromopyridine 
• 1350842-61-3 4-chloro-3-(4,4,5,5,-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline 
• 573764-31-5 3-iodo-4-chloroaniline 
• 100-00-5 4-chlorobenzonitrile 
• 425379-70-0 3-(2-chloro-5-nitro-phenyl)-pyridine 

Downstream Products

• 264617-18-7 (4-chloro-3-pyridin-3-yl-phenyl)-carbamic acid phenyl ester 

Relevant articles and documents

Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings

PI3K/Akt/mTOR and hedgehog (Hh) signalings are two important pathways in breast cancer, which are usually connected with the drug resistance and cancer migration. Many studies indicated that PI3K/Akt/mTOR inhibitors and Hh inhibitors displayed synergistic effects, and the combination of the two signaling drugs could delay drug resistance and inhibit cancer migration in breast cancer. Therefore, the development of molecules simultaneously inhibiting these two pathways is urgent needed. Based on the structures of PI3K inhibitor buparlisib and Hh inhibitor vismodegib, a series of hybrid structures were designed and synthesized utilizing rational drug design and computer-based drug design. Several compounds displayed excellent antiproliferative activities against several breast cancer cell lines, including triple-negative breast cancer (TNBC) MDA-MB-231 cell. Further mechanistic studies demonstrated that the representative compound 9i could inhibit both PI3K/Akt/mTOR and hedgehog (Hh) signalings by inhibiting the phosphorylation of S6K and Akt as well as decreasing the SAG elevated expression of Gli1. Compound 9i could also induce apoptosis remarkably in T47D and MDA-MB-231 cells. In the transwell assay, 9i showed significant inhibition on the migration of MDA-MB-231.